bcl-xL gene expression and apoptotic lymphoma cell counts in relation to clinical characteristics
. | . | bcl-xL gene expression in lymph node sections* . | . | . | bcl-xL gene expression in microdissected cells* . | . | . | No. apoptotic lymphoma cells by TUNEL assay . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics . | No. (%) . | Median . | Range . | P . | Median . | Range . | P . | Median . | Range . | P . | ||||||
| Performance status | .6394 | .9685 | .1596 | |||||||||||||
| 0-1 | 17 (63) | 5.4 | 1.2-28.1 | 9.1 | 1.9-59.6 | 40 | 5-108 | |||||||||
| 2-4 | 10 (37) | 6.8 | 3.2-22.4 | 12.5 | 5.4-45.9 | 29 | 5-58 | |||||||||
| Ann Arbor stage | .0873 | .1365 | .1832 | |||||||||||||
| I/II | 5 (19) | 3.5 | 1.5-5.4 | 8.1 | 2.9-15.2 | 45 | 38-96 | |||||||||
| III/IV | 22 (81) | 6.9 | 1.2-28.1 | 12.5 | 1.9-59.6 | 28 | 5-108 | |||||||||
| No. sites extranodal involvement | .0028 | .0020 | .0040 | |||||||||||||
| 0-1 | 16 (59) | 4.5 | 1.2-26.5 | 8.1 | 1.9-44.7 | 46 | 5-108 | |||||||||
| More than 1 | 11 (41) | 13.9 | 3.2-28.1 | 28.9 | 5.4-59.6 | 21 | 5-58 | |||||||||
| Serum LDH level | .0459 | .0478 | .0280 | |||||||||||||
| Normal or lower | 17 (63) | 5.1 | 1.2-26.8 | 8.1 | 1.9-45.9 | 45 | 5-108 | |||||||||
| Higher than normal | 10 (37) | 11.9 | 3.2-28.1 | 18.9 | 6.7-59.6 | 24 | 5-58 | |||||||||
| IPI score | .0360 | .0235 | .0143 | |||||||||||||
| Low risk to intermediate low risk | 16 (59) | 4.7 | 1.2-26.8 | 8.1 | 1.9-44.7 | 46 | 5-108 | |||||||||
| Intermediate high risk to high risk | 11 (41) | 13.2 | 3.2-28.1 | 28.3 | 5.4-59.6 | 22 | 5-58 | |||||||||
. | . | bcl-xL gene expression in lymph node sections* . | . | . | bcl-xL gene expression in microdissected cells* . | . | . | No. apoptotic lymphoma cells by TUNEL assay . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics . | No. (%) . | Median . | Range . | P . | Median . | Range . | P . | Median . | Range . | P . | ||||||
| Performance status | .6394 | .9685 | .1596 | |||||||||||||
| 0-1 | 17 (63) | 5.4 | 1.2-28.1 | 9.1 | 1.9-59.6 | 40 | 5-108 | |||||||||
| 2-4 | 10 (37) | 6.8 | 3.2-22.4 | 12.5 | 5.4-45.9 | 29 | 5-58 | |||||||||
| Ann Arbor stage | .0873 | .1365 | .1832 | |||||||||||||
| I/II | 5 (19) | 3.5 | 1.5-5.4 | 8.1 | 2.9-15.2 | 45 | 38-96 | |||||||||
| III/IV | 22 (81) | 6.9 | 1.2-28.1 | 12.5 | 1.9-59.6 | 28 | 5-108 | |||||||||
| No. sites extranodal involvement | .0028 | .0020 | .0040 | |||||||||||||
| 0-1 | 16 (59) | 4.5 | 1.2-26.5 | 8.1 | 1.9-44.7 | 46 | 5-108 | |||||||||
| More than 1 | 11 (41) | 13.9 | 3.2-28.1 | 28.9 | 5.4-59.6 | 21 | 5-58 | |||||||||
| Serum LDH level | .0459 | .0478 | .0280 | |||||||||||||
| Normal or lower | 17 (63) | 5.1 | 1.2-26.8 | 8.1 | 1.9-45.9 | 45 | 5-108 | |||||||||
| Higher than normal | 10 (37) | 11.9 | 3.2-28.1 | 18.9 | 6.7-59.6 | 24 | 5-58 | |||||||||
| IPI score | .0360 | .0235 | .0143 | |||||||||||||
| Low risk to intermediate low risk | 16 (59) | 4.7 | 1.2-26.8 | 8.1 | 1.9-44.7 | 46 | 5-108 | |||||||||
| Intermediate high risk to high risk | 11 (41) | 13.2 | 3.2-28.1 | 28.3 | 5.4-59.6 | 22 | 5-58 | |||||||||
Results in table calculated for n = 27 patients with follicular lymphoma.
Sample/calibrator ratio.